#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Prostate cancer Obesity Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Non-small cell lung cancer metastatic Dermatitis atopic Malignant melanoma Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Stargardt's disease Gastrointestinal disorder Rhabdomyosarcoma Gastrointestinal neuroendocrine tumour Necrotising enterocolitis neonatal Liver abscess Thrombocytosis Follicle centre lymphoma follicular grade I, II – III Hyperchylomicronaemia Systemic candida HER2 gene amplification Immunodeficiency congenital Ovarian epithelial cancer Chronic myelomonocytic leukaemia Warm autoimmune haemolytic anaemia More trials…

    Learn about Rare Diseases

    Angelman’s syndrome – Life with Disease Mucopolysaccharidosis II – Trials in Disease Mantle cell lymphoma stage IV – Trials in Disease Primary immunodeficiency syndrome – Diagnostics Testicular leiomyosarcoma – Diagnostics IgA nephropathy – Diagnostics Langerhans’ cell histiocytosis – Diagnostics Testicular leiomyosarcoma – Treatment Proteus syndrome – Treatment Congenital nephrogenic diabetes insipidus – Treatment More diseases…
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    S227928 Spesolimab Imipenem Dextromethorphan Hydrobromide Lisdexamfetamine Dimesylate Pembrolizumab Trimetazidine Dihydrochloride Alxn1850 AVTX-009 Hypromellose Rimegepant Clebopride Hydrogen Maleate Propafenone Hydrochloride Trametinib Dimethyl Sulfoxide Treosulfan Vosoritide Dexamethasone Ph. Eur. Patritumab Deruxtecan Tanimilast Keto-Leucine Calcium More therapies…

    Learn about Your Condition

    Supranuclear palsy Tumour of ampulla of Vater Microvillous inclusion disease Pulmonary congestion Graft versus host disease Meningococcal infection Synovial sarcoma recurrent Low cardiac output syndrome Adenocarcinoma pancreas Peripheral spondyloarthritis B-cell lymphoma Pneumonia External cephalic version Infertility Cholangitis sclerosing More diseases…
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Tacrolimus for prevention of post-ERCP pancreatitis in moderate- to high-risk patients

    Not yet recruiting

    3 1 1
    Investigated drugs:
    • Tacrolimus
    The Netherlands

  • Efficacy of intravenous prasinezumab versus placebo in Parkinson’s disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

    Not yet recruiting

    2 1 1
    Investigated diseases:
    • Parkinson’s disease
    Investigated drugs:
    • Prasinezumab
    • Sodium Chloride
    France Germany Italy Luxembourg Spain Sweden

  • Safety and efficacy of stopping versus maintenance dose of filgotinib, tofacitinib and upadacitinib in adult ulcerative colitis patients in deep remission

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    • Colitis ulcerative
    Investigated drugs:
    • Filgotinib
    • Tofacitinib
    • Upadacitinib
    France

  • Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

    Not yet recruiting

    4 1 1
    Investigated drugs:
    • Efgartigimod Alfa
    Austria Germany

  • Preventing Neuropathic Pain After Osteoporotic Vertebral Fracture with a 5% Lidocaine Patch in Adults

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    • Lidocaine
    France

  • Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

    Not yet recruiting

    3 1 1
    Investigated diseases:
    • Interstitial lung disease
    • Idiopathic pulmonary fibrosis
    • Pulmonary fibrosis
    Investigated drugs:
    • ADMILPARANT
    Austria Belgium Denmark Finland France Germany +8
Previous Page
1 … 661 662 663 664 665 … 1,616
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!